Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
作者： Christopher G. Willett , Dan G. Duda , Emmanuelle di Tomaso , Yves Boucher , Marek Ancukiewicz
关键词: Combination therapy 、 Chemoradiotherapy 、 Bevacizumab 、 Radiation therapy 、 Surgery 、 Urology 、 Neoadjuvant therapy 、 Medicine 、 Colorectal cancer 、 Cancer 、 Fluorouracil
摘要: Purpose To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer explore biomarkers for response. Patients Methods In a phase I/II study, 32 patients received four cycles therapy consisting of: infusion (5 or 10 mg/kg) on day 1 each cycle; fluorouracil (225 mg/m2/24 hours) during 2 to 4; external-beam irradiation (50.4 Gy 28 fractions over 5.5 weeks); surgery 7 weeks after completion all therapies. We measured molecular, cellular, physiologic before treatment, monotherapy, combination therapy. Results Tumors regressed from mass mean size 5 cm (range, 3 12 cm) an ulcer/scar 2.4 0.7 6.0 patients. Histologic examination revealed either no varying numbers scattered cells bed fibrosis at primary site. This treatment resulted actuari...
harvard.edu
sci-hub.se 参考文章(18)
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren, Napoleone Ferrara, Gwen Fyfe, Beth Rogers, Robert Ross, Fairooz Kabbinavar, None, BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER The New England Journal of Medicine. ,vol. 350, pp. 2335- 2342 ,(2004) , 10.1056/NEJMOA032691
J. Drevs, U. Zirrgiebel, C.I.M. Schmidt-Gersbach, K. Mross, M. Medinger, L. Lee, J. Pinheiro, J. Wood, A.L. Thomas, C. Unger, A. Henry, W.P. Steward, D. Laurent, D. Lebwohl, M. Dugan, D. Marmé, Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials web science. ,vol. 16, pp. 558- 565 ,(2005) , 10.1093/ANNONC/MDI118
John M.L. Ebos, Christina R. Lee, Elena Bogdanovic, Jennifer Alami, Paul Van Slyke, Giulio Francia, Ping Xu, Anthony J. Mutsaers, Daniel J. Dumont, Robert S. Kerbel, Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth Cancer Research. ,vol. 68, pp. 521- 529 ,(2008) , 10.1158/0008-5472.CAN-07-3217
C. H. Crane, C. Eng, B. W. Feig, P. Das, J. M. Skibber, G. J. Chang, R. A. Wolff, S. Krishnan, D. M. Maru, L. M. Ellis, M. A. Rodriguez-Bigas, Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer Journal of Clinical Oncology. ,vol. 26, pp. 4091- 4091 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4091
Anne-Marie Mandard, Frédéric Dalibard, Jean-Claude Mandard, Jacques Marnay, Michel Henry-Amar, Jean-François Petiot, Alain Roussel, Jacques-Henry Jacob, Philippe Segol, Guy Samama, Jean-Marie Ollivier, Sylvie Bonvalot, Marc Gignoux, Pathologic Assessment of Tumor Regression After Preoperative Chemoradiotherapy of Esophageal Carcinoma. Clinicopathologic Correlations Cancer. ,vol. 73, pp. 2680- 2686 ,(1994) , 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
Dan G Duda, Kenneth S Cohen, David T Scadden, Rakesh K Jain, A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood Nature Protocols. ,vol. 2, pp. 805- 810 ,(2007) , 10.1038/NPROT.2007.111
Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler, Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature Reviews Clinical Oncology. ,vol. 3, pp. 24- 40 ,(2006) , 10.1038/NCPONC0403
R. K. Jain, Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science. ,vol. 307, pp. 58- 62 ,(2005) , 10.1126/SCIENCE.1104819
Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding, Robert A. Figlin, Michelle S. Ginsberg, Sindy T. Kim, Charles M. Baum, Samuel E. DePrimo, Jim Z. Li, Carlo L. Bello, Charles P. Theuer, Daniel J. George, Brian I. Rini, Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 24, pp. 16- 24 ,(2006) , 10.1200/JCO.2005.02.2574
Christopher G Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G Duda, Lance L Munn, Ricky T Tong, Daniel C Chung, Dushyant V Sahani, Sanjeeva P Kalva, Sergey V Kozin, Mari Mino, Kenneth S Cohen, David T Scadden, Alan C Hartford, Alan J Fischman, Jeffrey W Clark, David P Ryan, Andrew X Zhu, Lawrence S Blaszkowsky, Helen X Chen, Paul C Shellito, Gregory Y Lauwers, Rakesh K Jain, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Medicine. ,vol. 10, pp. 145- 147 ,(2004) , 10.1038/NM988